SARS-CoV-2 IgG seroprevalence surveys in blood donors before the vaccination campaign, France 2020-2021.
Immune response
Immunology
Virology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
21 Apr 2023
21 Apr 2023
Historique:
received:
07
07
2022
revised:
20
12
2022
accepted:
11
02
2023
pubmed:
24
2
2023
medline:
24
2
2023
entrez:
23
2
2023
Statut:
ppublish
Résumé
We conducted a cross-sectional study for SARS-CoV-2 anti-S1 IgG prevalence in French blood donors (n = 32605), from March-2020 to January-2021. A mathematical model combined seroprevalence with a daily number of hospital admissions to estimate the probability of hospitalization upon infection and determine the number of infections while correcting for antibody decay. There was an overall seroprevalence increase over the study period and we estimate that ∼15% of the French population had been infected by SARS-CoV-2 by January-2021. The infection/hospitalization ratio increased with age, from 0.31% (18-30yo) to 4.5% (61-70yo). Half of the IgG-S1 positive individuals had no detectable antibodies 4 to 5 months after infection. The seroprevalence in group O donors (7.43%) was lower (p = 0.003) than in A, B, and AB donors (8.90%). We conclude, based on seroprevalence data and mathematical modeling, that a large proportion of the French population was unprotected against severe disease prior to the vaccination campaign.
Identifiants
pubmed: 36818722
doi: 10.1016/j.isci.2023.106222
pii: S2589-0042(23)00299-7
pmc: PMC9930380
doi:
Types de publication
Journal Article
Langues
eng
Pagination
106222Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Clin Infect Dis. 2021 Jul 15;73(2):328-331
pubmed: 32750119
Acta Haematol. 2021;144(5):580-584
pubmed: 33878755
J Clin Virol. 2022 Jan;146:105045
pubmed: 34861600
Infection. 2021 Dec;49(6):1187-1194
pubmed: 34132990
Int J Infect Dis. 2021 Mar;104:242-249
pubmed: 33326874
Transfusion. 2021 Dec;61(12):3381-3389
pubmed: 34647620
Eur J Prev Cardiol. 2020 Sep;27(13):1436-1437
pubmed: 32343152
Lancet Infect Dis. 2022 Dec;22(12):e370-e376
pubmed: 36057267
Int J Epidemiol. 2021 Nov 10;50(5):1458-1472
pubmed: 34293141
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930
Clin Microbiol Infect. 2021 Jun;27(6):914.e1-914.e4
pubmed: 33677083
BMJ Open. 2021 Apr 1;11(4):e045425
pubmed: 33795310
Nat Commun. 2020 Nov 12;11(1):5744
pubmed: 33184284
J Infect Dis. 2021 Nov 16;224(9):1489-1499
pubmed: 34282461
Lancet Public Health. 2021 Jun;6(6):e408-e415
pubmed: 33838700
JAMA. 2020 Oct 27;324(16):1677-1679
pubmed: 32926078
Lancet Healthy Longev. 2021 Dec;2(12):e811-e819
pubmed: 34873592
Lancet Respir Med. 2020 Apr;8(4):e20
pubmed: 32171067
Antiviral Res. 2020 Sep;181:104880
pubmed: 32679056
JAMA. 2021 Oct 12;326(14):1400-1409
pubmed: 34473201
Euro Surveill. 2020 Jul;25(28):
pubmed: 32700672
J Infect Dis. 2022 Jan 18;225(2):219-228
pubmed: 34788834
J Intern Med. 2021 Sep;290(3):666-676
pubmed: 34008203
JAMA. 2005 Mar 23;293(12):1450-1
pubmed: 15784866
Clin Infect Dis. 2022 Mar 9;74(5):871-881
pubmed: 34111244
Emerg Infect Dis. 2022 Mar;28(3):672-683
pubmed: 35202525
Infect Dis Now. 2021 Jun;51(4):380-382
pubmed: 33521775
PLoS Comput Biol. 2021 Sep 20;17(9):e1009436
pubmed: 34543264
Transfus Med Rev. 2021 Jul;35(3):8-15
pubmed: 34376289
Viruses. 2021 Jan 22;13(2):
pubmed: 33499228